AstraZeneca says FDA approves Baxfendy for adults with hypertension in US

• AstraZeneca won US FDA clearance for Baxfendy (baxdrostat) as the first aldosterone synthase inhibitor for adults with hypertension whose blood pressure remains uncontrolled on combination therapy.
• The decision was backed by the BaxHTN Phase III study, where Baxfendy 2 mg cut seated systolic blood pressure by 15.7 mmHg from baseline, equal to a 9.8 mmHg placebo-adjusted drop at week 12.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.